Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesInvasive meningococcal disease in Malta: an epidemiological overview, 1994–2007
Journal of Medical Microbiology, 10/21/09
Muscat M et al. – The findings underscore the importance of enhancing laboratory surveillance of the disease, including characterization of the meningococci. Until vaccines against a broad range of serogroup B meningococci become available for universal use, the main methods of control remain the early treatment of cases and the prevention of secondary cases.
Mark Muscat, 10/21/09
| Since the mid-90s, meningococcal disease has acquired prominence on the island country of Malta on account of its resurgence after three decades of negligible reported cases. This article describes the epidemiology of the disease in Malta between 1994 and 2007. 233 cases were notified during this period. The upsurge of the disease became noticeable in 1996, placed Malta amongst countries with the highest incidence for the disease in Europe during the same period. The average age of the notified cases was 14 years and 165 (70%) were below 20 years of age. The disease claimed the lives of 28 patients giving an overall case fatality rate of 12%. Collectively, the number of cases peaked in late winter/early spring and again in summer. This is unlike the seasonal pattern observed in other European countries where the disease occurs mostly in winter. Laboratory investigations carried out on 114 cases showed that in Malta, serogroup B formed the largest proportion (76%) as in the rest of Europe, followed by serogroup C (16%). A particular strain of serogroup B identified as B:4:P1.19,15 has dominated Malta during the study period. The eventual development of a safe and effective vaccine against serogroup B strains for universal use would be a major public health tool to control meningococcal disease in Malta. Until then, the main methods of control remain the early treatment of cases and the prevention of secondary cases. The latter public health measures primarily involve the identification of close contacts and the administration of appropriate antibiotics. |
Today in CNS Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Epidemiology, Prevention and Management of Ventriculoperitoneal Shunt Infections in Children
Pediatric Neurosurgery, 11/11/09
Penetration of Colistin into Cerebrospinal Fluid
Antimicrobial Agents and Chemotherapy, 11/05/09
Ureaplasma: Pathogen or Passenger in Neonatal Meningitis
The Pediatric Infectious Disease Journal, 11/24/09
Sponsor
Article Search
Sponsor